Application of caulophine in preparation of medicament for resisting benign prostatic hyperplasia

Abstract

The invention discloses an application of caulophine in the preparation of a medicament for resisting benign prostatic hyperplasia. The present invention finds for the first time that caulophine has asignificant effect for resisting benign prostatic hyperplasia, and has mild and long-lasting effects. The invention provides a new choice and idea for the treatment of benign prostatic hyperplasia, and also contributes to the development of the technical field. The caulophine is a compound with a defined chemical structure, is available to quantifiable feed when used for preparing medicines, andis used for preparing modern dosage forms. The caulophine is highly safe and has the potential to develop into a drug for treating benign prostatic hyperplasia.

Description

technical field [0001] The present invention relates to the new medical application of ramectine, in particular to the application of ramectine in the preparation of anti-benign prostatic hyperplasia medicine. Background technique [0002] Benign prostatic hyperplasia is a common physiological lesion in elderly men. Its incidence is high, it is painful, and it is difficult to cure it. There is a substantial increase compared with the disease, and it has become one of the most common geriatric diseases among elderly men in my country. [0003] The treatment of benign prostatic hyperplasia can be divided into surgical treatment and drug treatment. However, since most patients with benign prostatic hyperplasia are old, most patients may suffer from serious cardiovascular and cerebrovascular complications, and surgical treatment has a higher risk, so benign prostatic hyperplasia Drug treatment for prostate enlargement is very important. [0004] At present, the drugs used clini...

AI Technical Summary

Problems solved by technology

[0003] The treatment of benign prostatic hyperplasia can be divided into surgical treatment and drug treatment. However, since most patients with benign prostatic hyperplasia are old, most patients may suffer from serious cardiovascular and cerebrovascular complications, and surgical treatment has a higher risk, so benign prostatic hyperplasia Drug treatment for prostate enlargement is very important

[0004] At present, the drugs used clinically to treat benign prostatic hyperplasia mainly include: (1) synthetic drugs that only target a specific target, such as 5α-reductase inhibitors, α 1 However, due to the complex pathogenesis of benign prostatic hyperplasia, the course of treatment is generally longer, and these drugs can cause adverse reactions such as headache and sexual dysfunction in long-term use; (2) natural product preparations, because their effects are relatively mild , less adverse reactions, more suitable for long-term use

And because benign prostatic hyperplasia is related to multiple receptors and enzymes, the pathogenesis is complex, and it is considered to be the result of the synergistic effect of multiple factors, and the treatment of benign prostatic hyperplasia by natural product preparations may work on multiple targets

At present, there is no research report on the anti-benign prostatic hyperplasia activity of ramectine

Images